Who Owns Opko Company?

Opko Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who really controls OPKO Health?

OPKO's ownership blends broad public float with concentrated insider power, led by Chairman‑CEO Phillip Frost and his family trust. Major institutional investors and BioReference's 2015 acquisition reshaped control and strategic direction.

OPKO combines diagnostics, pharmaceuticals and royalty streams like Pfizer's Ngenla; Frost's stake and institutional holders together determine governance and capital choices.

Explore deeper ownership dynamics and strategic pressure points in the Opko Porter's Five Forces Analysis.

Founders and early ownership of Opko trace to 2007, when Phillip Frost, M.D., Jane H. Hsiao, Ph.D., MBA, and Steven D. Rubin consolidated assets via reverse mergers and roll‑ups to form the Miami‑headquartered platform; ownership from inception was insider‑heavy with Frost’s vehicle holding controlling influence.

Founding trio

Phillip Frost, Jane Hsiao and Steven Rubin led the roll‑up strategy that created the modern company in 2007.

Insider‑heavy ownership

Early SEC filings (2007–2009) show Frost as the dominant beneficial owner; Hsiao and Rubin held meaningful blocks aligned with operating roles.

Frost’s control vehicle

Frost Gamma Investments Trust served as the principal vehicle through which Frost exercised controlling influence over Opko ownership and voting.

Seed investors

Seed and friends‑and‑family rounds involved Frost’s Miami network; these private placements supplemented insider holdings without displacing founder control.

Equity as currency

Founders used equity to fund acquisitions and growth, accepting dilution to scale while retaining founder‑led governance and voting influence.

Governance protections

Early employment and equity agreements included vesting and buy‑sell mechanics to anchor long‑term control and prevent founder disputes.

Early public filings did not publish a day‑one share split, but 2007–2009 disclosures and proxy statements consistently list Frost as the largest beneficial owner, followed by Hsiao and Rubin; these positions shaped Opko ownership and voting dynamics into the 2010s.

Key facts and implications

The founders’ structure explains who owns Opko and how control was retained during rapid expansion; use these pointers to research current Opko ownership and major shareholders.

• Founders: Phillip Frost, Jane H. Hsiao, Steven D. Rubin.
• 2007–2009 filings show Frost as dominant beneficial owner; Hsiao and Rubin next largest insiders.
• Governance: Frost Gamma Investments Trust provided concentrated voting influence.
• Acquisition strategy relied on issuing equity, accepting dilution to preserve founder‑led control.

For related context on business model and revenue implications of founder‑led control, see Revenue Streams & Business Model of Opko.

Opko SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events reshaping Opko ownership include early equity financings and acquisitions (2007–2014), the 2015 all‑stock acquisition of BioReference Labs, and the 2014–2023 Pfizer collaboration culminating in Ngenla FDA approval in 2023, which together expanded the shareholder base and shifted voting influence while preserving insider control.

By 2024–2025 Opko had roughly the high‑700 million range in basic shares outstanding and a market capitalization in the low‑to‑mid single‑digit billions; insider filings (Form 4s) show continued purchases by Frost that anchor strategic, long‑horizon R&D and royalty‑driven strategy. See a concise corporate background at Brief History of Opko

Ownership evolution highlights

Snapshot of who owns Opko and how control is concentrated.

• Insider control: Phillip Frost via Frost Gamma — largest single beneficial owner, filings show high‑30s%
• Other insiders: Jane H. Hsiao, Ph.D., MBA and Steven D. Rubin hold multi‑million‑share positions
• Institutions: Vanguard and BlackRock hold mid‑single‑digit stakes; passive index funds add liquidity
• Public float: retail and small institutions widely hold remaining shares, improving trading depth

Opko PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of the latest proxy period, Opko Pharmaceuticals' board comprises founder‑operators and independent directors: Phillip Frost, M.D. (Chairman and CEO); Jane H. Hsiao, Ph.D., MBA (Vice Chairman); Steven D. Rubin (Executive Vice President); Richard C. Pfenniger, Jr. (independent); John A. Paganelli (independent); and Robert A. Berman (independent). Insiders Frost, Hsiao and Rubin form the founder‑operator bloc while independents supply healthcare, finance and governance expertise.

Voting power follows a one‑share‑one‑vote structure with no disclosed dual‑class or golden‑share arrangements; economic and voting control align with ownership stakes, giving Phillip Frost's trust outsized influence given its large percentage holding reported in 2024–2025 filings. Recent governance debates have centered on combined chair/CEO roles, board independence and director refreshment rather than proxy fights.

Board & Voting Snapshot

Key points on who owns Opko and how control is exercised.

• Board mix: 3 insiders (Frost, Hsiao, Rubin) vs 3 independents.
• Voting: one‑share‑one‑vote; no dual‑class structure disclosed.
• Control: Phillip Frost’s trust reported majority or largest block influence in recent filings.
• Governance focus: independence, chair/CEO consolidation, and refreshment cadence.

For additional market positioning and competitor context, see Competitors Landscape of Opko.

Opko Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Opko ownership has shifted since 2023 as royalty cash flows and diagnostics stabilization raised visibility; index fund inflows and continued insider purchases—especially by Frost—have reinforced a mixed base of passive institutions and concentrated insider voting control.

Key catalysts from 2023–2025 include U.S. approval and commercialization of Pfizer’s Ngenla which highlighted OPKO’s royalty economics, attracting passive and sector funds; BioReference margin stabilization came from cost discipline and portfolio optimization.

Ownership concentration

Despite historic dilution from share issuance, insider accumulation keeps voting influence concentrated under Frost, making him the decisive bloc on governance matters.

Institutional trends

Passive index funds and healthcare specialists have increased exposure as liquidity and market cap stabilized, reflected in successive 13F filings and ETF flows.

Retail impact

Retail ownership remains a meaningful fraction of the float, contributing to trading volatility around royalty news, Form 4s, and diagnostics updates.

Forward signals

Management and analysts emphasize leveraging royalty cash flows and BioReference efficiencies over transformative equity‑financed M&A, implying a stable ownership mix near term; larger strategic moves would likely preserve insider influence under one‑share‑one‑vote.

For context on corporate priorities and governance, see Mission, Vision & Core Values of Opko for related company-level direction and values.

Opko Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔